A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 15 Jan 2015 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
- 15 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 18 Sep 2014 New trial record